Ekso Bionics (EKSO) 10-K 3 Mar 25 2024 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2024	Feb. 28, 2025	Jun. 28, 2024
Document Information [Line Items]
Entity Central Index Key	0001549084
Entity Registrant Name	EKSO BIONICS HOLDINGS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Entity File Number	001-37854
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	99-0367049
Entity Address, Address Line One	101 Glacier Point, Suite A
Entity Address, City or Town	San Rafael
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94901
City Area Code	510
Local Phone Number	984-1761
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	EKSO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 18,771,767
Entity Common Stock, Shares Outstanding		24,824,762
Auditor Name	WithumSmith+Brown, PC
Auditor Location	San Francisco, California
Auditor Firm ID	100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and restricted cash	$ 6,493	$ 8,638
Accounts receivable, net of allowances of $33 and $79, respectively	7,238	5,645
Inventories	4,571	5,050
Prepaid expenses and other current assets	541	875
Total current assets	18,843	20,208
Property and equipment, net	1,577	2,018
Right-of-use assets	788	977
Intangible assets, net	4,580	4,892
Goodwill	431	431
Other assets	433	392
Total assets	26,652	28,918
Current liabilities:
Accounts payable	1,552	1,847
Accrued liabilities	2,352	2,664
Deferred revenues, current	1,956	1,993
Notes payable, current	1,250	1,250
Lease liabilities, current	427	363
Total current liabilities	7,537	8,117
Deferred revenues	1,920	2,169
Notes payable, net	3,854	4,832
Lease liabilities	452	723
Warrant liabilities	1	366
Other non-current liabilities	181	105
Total liabilities	13,945	16,312
Commitments and contingencies (Note 15)
Stockholders' equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued and outstanding as of December 31, 2024 and 2023	0	0
Common stock, $0.001 par value; 141,429 shares authorized; 22,203 and 14,848 shares issued and outstanding as of December 31, 2024 and 2023, respectively	22	15
Additional paid-in capital	262,203	251,580
Accumulated other comprehensive income	957	156
Accumulated deficit	(250,475)	(239,145)
Total stockholders' equity	12,707	12,606
Total liabilities and stockholders' equity	$ 26,652	$ 28,918

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Allowance for doubtful accounts	$ 33	$ 79
Preferred Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, shares authorized (in shares)	10,000	10,000
Preferred Stock, shares issued (in shares)	0	0
Preferred Stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	141,429	141,429
Common stock, issued (in shares)	22,203	14,848
Common stock, outstanding (in shares)	22,203	14,848

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Revenue		$ 17,925	$ 18,279
Cost of revenue		8,414	9,200
Gross profit		9,511	9,079
Operating expenses:
Sales and marketing		7,308	8,472
Research and development		3,874	5,025
General and administrative		8,789	10,694
Total operating expenses		19,971	24,191
Loss from operations		(10,460)	(15,112)
Other (expense) income, net:
Interest expense, net		(269)	(302)
Gain (loss) on revaluation of warrant liabilities		474	(133)
Loss on modification of warrant		(109)	0
Unrealized (loss) gain on foreign exchange		(965)	412
Other expense, net		(1)	(63)
Total other (expense) income, net		(870)	(86)
Net loss		(11,330)	(15,198)
Foreign currency translation adjustments		801	(407)
Comprehensive loss		$ (10,529)	$ (15,605)
Net loss per share applicable to common shareholders, basic and diluted (in dollars per share)		$ (0.56)	$ (1.1)
Weighted average number of shares outstanding, basic and diluted (in shares)	[1]	20,161	13,867
[1]Includes the weighted average effect of the Pre-Funded Warrant, the exercise of which requires nominal consideration for the delivery of the shares of common stock.

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	0	13,203
Balance at Dec. 31, 2022	$ 0	$ 13	$ 248,813	$ 563	$ (223,947)	$ 25,442
Net loss	$ 0	$ 0	0	0	(15,198)	(15,198)
Equity financing, net (in shares)	0	451
Equity financing, net	$ 0	$ 1	660	0	0	$ 661
Equity incentive plan (in shares)	0	1,033
Matching contribution to 401(k) plan (in shares)	0	161				161
Matching contribution to 401(k) plan	$ 0	$ 1	249	0	0	$ 249
Stock-based compensation	0	0	1,858	0	0	1,858
Foreign currency translation adjustments	$ 0	$ 0	0	(407)	0	(407)
Balance (in shares) at Dec. 31, 2023	0	14,848
Balance at Dec. 31, 2023	$ 0	$ 15	251,580	156	(239,145)	12,606
Net loss	$ 0	$ 0	0	0	(11,330)	(11,330)
Equity financing, net (in shares)	0	6,172
Equity financing, net	$ 0	$ 6	9,014	0	0	$ 9,020
Equity incentive plan (in shares)	0	685
Matching contribution to 401(k) plan (in shares)	0	163				163
Matching contribution to 401(k) plan	$ 0	$ 0	237	0	0	$ 237
Stock-based compensation	0	0	1,372	0	0	1,372
Foreign currency translation adjustments	$ 0	$ 0	0	801	0	801
Exercise of Pre-Funded Warrants (in shares)	0	335
Exercise of Pre-Funded Warrants	$ 0	$ 0	0	0	0	0
Balance (in shares) at Dec. 31, 2024	0	22,203
Balance at Dec. 31, 2024	$ 0	$ 22	$ 262,203	$ 957	$ (250,475)	$ 12,707

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating activities
Net loss	$ (11,330)	$ (15,198)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1,608	1,698
Changes in provision for credit losses on accounts receivable	171	72
Common stock contribution to 401(k) plan	257	378
Stock-based compensation expense	1,373	1,858
(Gain) loss on revaluation of warrant liabilities	(474)	133
Loss on modification of warrant	109	0
Unrealized loss (gain) on foreign currency transactions	965	(412)
Changes in operating assets and liabilities:
Accounts receivable	(1,967)	(1,208)
Inventories	257	232
Prepaid expenses and other assets current and noncurrent	329	(158)
Accounts payable	(288)	(1,307)
Accrued, lease and other current and noncurrent liabilities	(599)	(134)
Deferred revenues	(257)	1,992
Net cash used in operating activities	(9,846)	(12,054)
Investing activities
Acquisition of property and equipment	(37)	(157)
Net cash used in investing activities	(37)	(157)
Financing activities
Principal payments under note payable	(1,250)	(313)
Proceeds from issuance of common stock, net	9,019	661
Net cash provided by financing activities	7,769	348
Effect of exchange rate changes on cash	(31)	(24)
Net decrease in cash	(2,145)	(11,887)
Cash and restricted cash at beginning of the year	8,638	20,525
Cash and restricted cash at end of the year	6,493	8,638
Supplemental disclosure of cash flow activities
Cash paid for interest	182	191
Cash paid for income taxes	8	45
Supplemental disclosure of non-cash activities
Share issuance for common stock contribution to 401(k) plan	238	250
Transfer of inventory (from) to property and equipment	199	(82)
Initial recognition of (adjustment to) operating lease liabilities and right of use assets	$ 180	$ (10)

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2024
Insider Trading Arr Line Items
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Risk Management and Strategy
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We perform a formal risk assessment each year. As part of the Company's risk assessment, we consider the potential for cybersecurity threats, including but not limited to interruptions, outages and breaches to its operational and financial systems. We have policies, processes, internal controls and tools to assess, identify, and manage material risks from potential cybersecurity threats. We utilize a combination of cybersecurity awareness training, manual processes, specialized software and automated tools, and third-party assessments to build our cybersecurity program. We engage third-party service providers, with significant information technology and cybersecurity experience, to assist with designing, implementing and managing our information technology infrastructure and cybersecurity program. We are also currently developing a cybersecurity incident response plan that establishes a formal framework for responding to cybersecurity incidents, including defining what constitutes a reportable cybersecurity incident; establishing specific escalation and communication channels; identifying parties responsible for managing and responding to each incident; and other preparedness and response activities.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Governance As of the date of this Annual Report on Form 10 not 1A. We are subject to cybersecurity risks to our systems, infrastructure, and technology, and data processed by us or third No not may not may no
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee of our Board of Directors (the "Audit Committee") provides oversight over our internal control program, including the adequacy and effectiveness of our information technology infrastructure and cybersecurity program. Each quarter, management provides updates to the Audit Committee regarding its internal control program, including any significant changes to its information technology infrastructure or cybersecurity program. Management also reports any material risks from cybersecurity threats to the Audit Committee. Management periodically provides the Audit Committee with updates on cybersecurity risks and/or trends.
Cybersecurity Risk Role of Management [Text Block]	Our management team, specifically the chief executive officer and the chief financial officer, are responsible for the day-to-day administration of our business operations, including our risk management of cybersecurity risks. Management is responsible for the design and implementation of policies, processes and internal controls to manage our cybersecurity risks. Our management team regularly meets with their information technology resources, including its third-party service providers, to ensure that we are appropriately positioned to manage our cybersecurity risks. Our management team also sponsors periodic cybersecurity awareness training for employees.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets exoskeleton products that augment human strength, endurance and mobility. The primary end market for our exoskeleton technology is healthcare, where our technology primarily serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and multiple sclerosis ("MS"), and spinal cord injury ("SCI") to rehabilitate and to stand and walk in neurorehabilitation settings and, for patients with a SCI, for home and community use, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005, Unless otherwise indicated, all dollar and share amounts included in these notes to the consolidated financial statements are in thousands. Liquidity and Going Concern As of December 31, 2024 December 31, 2024 December 31, 2024 As described in Note 9. Notes Payable, net August 2026. December 31, 2024 December 31, 2024 Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one one no 12 The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies and Estimates	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation and Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). The consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Reclassifications For the year ended December 31, 2024, one 6. Property and Equipment, net Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not Foreign Currency The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying consolidated statements of operations and comprehensive loss. Accumulated Other Comprehensive Income The Company's accumulated other comprehensive income consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income presented on the consolidated balance sheets for the year ended December 31, 2024 2023, Accumulated Other Comprehensive Income Balance as of December 31, 2022 $ 563 Net unrealized loss on foreign currency translation (407 ) Balance as of December 31, 2023 156 Net unrealized gain on foreign currency translation 801 Balance as of December 31, 2024 $ 957 Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company's cash balances held in domestic banks are deposited into accounts at various financial institutions with each balance under the $250 $100 two The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not not The Company had two 10% December 31, 2024 December 31, 2023 The Company had one customer with sales of 10% December 31, 2024 2023 Accounts Receivable and Allowance for Credit Losses The Company carries accounts receivable at invoiced amounts less an allowance (or "provision") for credit losses. The Company reviews accounts receivables for collectability and determines an allowance for credit losses. The allowance for credit losses on accounts receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on historical bad debt expense, the aging of the accounts, known troubled accounts, customer payment history, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 90 not December 31, 2024 2023 December 31, 2024 2023, 2022 Inventories Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first first Inventories consisted of the following: December 31, 2024 2023 Raw materials $ 3,551 $ 4,298 Work in progress 177 290 Finished goods 843 462 Inventories $ 4,571 $ 5,050 Leases The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases not may Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. Leases with an initial term of 12 not Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally ranging from three 10 The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not None December 31, 2024 2023 December 31, 2024 2023 Goodwill The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. The Company performs an annual impairment assessment, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill. Such indicators include, among others, material departures from projected sales volume, deteriorating gross margins, and uncertainties regarding continued commercialization as a result of changing business strategies. The Company determined no impairment existed for the years ended December 31, 2024 December 31, 2023 Intangible Assets Other intangible assets include developed technology, acquired intellectual property, and customer relationships, in the case of finite-lived intangibles, and trade names in the case of indefinite-lived intangibles. Finite-lived intangibles are amortized over their estimated useful lives and are tested for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of the assets may not The Company determined no impairment existed for the year ended December 31, 2024 December 31, 2023 Warrant Valuation The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that it may Where there is a possibility that the Company may Going Concern The Company assesses its ability to continue as a going concern in accordance with ASC 205 40, Presentation of Financial Statements Going Concern Revenue Recognition The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers five For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not The Company generally does not not December 31, 2024 2023, not not Research and Development Research and development costs consist of costs incurred for internal research and development activities. These costs primarily include salaries and other personnel-related expenses, contractor fees, prototype materials, facility costs, supplies, and depreciation of equipment associated with the design and development of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have not not Stock-based Compensation The Company measures stock-based compensation expense for restricted stock units (“RSUs”) and performance stock units ("PSUs") made to employees and directors based on the Company’s closing stock price on the date of grant and recognizes the value on a straight-line basis over the requisite service periods of the awards. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For awards with performance-based conditions, at the point that it becomes probable that the performance conditions will be met, the Company records a cumulative catch-up of the expense from the grant date to the current date, and then amortizes the remainder of the expense over the remaining service period. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur. The Company measures stock-based compensation expense for stock options granted to employees and directors based on the estimated fair value of the award on the date of grant and recognizes the fair value on a straight-line basis over the requisite service periods of the awards. The Company determines the fair value of stock options on the date of grant using the Black-Scholes Model, which is affected by the Company’s stock price and assumptions regarding a number of subjective variables. These variables include, but are not 14. The Company has, from time to time, modified the terms of its stock options and RSUs to certain employees and directors. The Company accounts for the incremental compensation cost, which is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification, as an expense for vested awards or over the remaining service (vesting) period for unvested awards. Accounting Pronouncements Adopted in 2024 November 2023, No. 2023 07, 280 2023 07" 2023 07 2023 07 December 15, 2023, December 15, 2024. 10 December 31, 2024. not 16. Segment Disclosures Recent Accounting Pronouncements In December 2023, No. 2023 09, 740 2023 09" 2023 09 December 15, 2024, not 2023 09 In November 2024, No. 2024 03, 220 40 2024 03” December 15, 2026, December 15, 2027,

Note 3 - Net Loss Per Share of

Note 3 - Net Loss Per Share of Common Stock	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	3. Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed, when applicable, using the weighted average number of shares of common stock, adjusted to include conversion of "in-the-money" stock options and warrants for common stock and release of common stock in connection with restricted stock units during the period, net of tax as follows: Years ended December 31, 2024 2023 Numerator Adjusted net loss used for dilution calculation $ (11,330 ) $ (15,198 ) Denominator Weighted-average number of shares outstanding (1) 20,161 13,867 Effect of potential dilutive shares — — Dilutive weighted-average number of shares outstanding 20,161 13,867 Net loss per share, basic and diluted $ (0.56 ) $ (1.10 ) ( 1 The following table sets forth potential shares of common stock that are not Years ended December 31, 2024 2023 Options to purchase common stock 183 252 Restricted stock units 1,025 1,305 Warrants for common stock (1) 12,995 1,240 Total common stock equivalents 14,203 2,797 ( 1 December 31, 2024. December 31, 2024, September 2024 12. Capitalization and Equity Structure — Warrants

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two may • Level 1 • Level 2 1 not • Level 3 no 3 The Company’s fair value hierarchies for its financial assets and liabilities which require fair value measurement on a recurring basis are as follows: Total Level 1 Level 2 Level 3 December 31, 2024 Liabilities Warrant liabilities $ 1 $ — $ — $ 1 December 31, 2023 Liabilities Warrant liabilities $ 366 $ — $ — $ 366 During the years ended December 31, 2024 2023 no 1, 2, 3 not The following table sets forth a summary of the changes in the fair value of Company’s Level 3 December 31, 2024 2023, Warrant Liability Balance as of December 31, 2022 $ 233 Loss on revaluation of warrants issued in 2021, June 2020, December 2019, and May 2019 equity financings 133 Balance as of December 31, 2023 $ 366 Gain on revaluation of warrants issued in 2021, June 2020, December 2019, and May 2019 equity financings $ (474 ) Loss on modification of warrant 109 Balance as of December 31, 2024 $ 1 See Note 12 Capitalization and Equity Structure Warrants

Note 5 - Revenue

Note 5 - Revenue	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	5. The Company’s revenue is primarily generated through the sale and subscription of the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal devices, along with the sale of support and maintenance contracts. Revenue from device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of these devices. Support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements ranging from 12 to 48 months. Revenue is recognized evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the contract term, typically over 24 Deferred Revenue Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts, but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service. Deferred revenue consisted of the following: December 31, 2024 December 31, 2023 Deferred extended maintenance and support $ 3,669 $ 3,993 Deferred device and advances 207 169 Total deferred revenues 3,876 4,162 Less current portion (1,956 ) (1,993 ) Deferred revenues, non-current $ 1,920 $ 2,169 On September 25, 2023, Deferred revenue activity consisted of the following for the years ended December 31, 2024 December 31, 2023 Year Ended December 31, 2024 Year Ended December 31, 2023 Beginning balance $ 4,162 $ 2,153 Deferral of revenue 3,331 4,727 Recognition of deferred revenue (3,617 ) (2,718 ) Ending balance $ 3,876 $ 4,162 The Company expects to recognize approximately $1,956 of the deferred revenue during 2025 2026 In addition to deferred revenue, the Company has a non-cancellable backlog of $3,364, which includes customer orders received but not 2025 2026, 2025 2026. Disaggregation of Revenue The following table disaggregates the Company’s revenue by major source for the year ended December 31, 2024 Total Device revenue $ 13,323 Service and support 3,121 Subscriptions 527 Parts and other 954 $ 17,925 The following table disaggregates the Company’s revenue by major source for the year ended December 31, 2023 Total Device revenue $ 14,132 Service and support 2,821 Subscriptions 967 Parts and other 359 $ 18,279 The Company operates in the following regions: ( 1 2 3 10% December 31, 2024 2023 Year ended December 31, 2024 2023 United States $ 9,712 $ 12,500 Other 421 495 Americas 10,133 12,995 France 3,006 181 Other 2,936 3,584 EMEA 5,942 3,765 APAC 1,850 1,519 $ 17,925 $ 18,279

Note 6 - Property and Equipment

Note 6 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and equipment, net consisted of the following: Estimated December 31, Life (Years) 2024 2023 Company-owned device fleet 1-5 $ 2,572 $ 2,828 Molds and other tools 5-7 1,424 1,418 Machinery and equipment 3-7 380 401 Software 3-5 234 234 Leasehold improvement 1-3 194 178 Furniture and office equipment 3-7 114 114 4,918 5,174 Accumulated depreciation and amortization (3,341 ) (3,156 ) Property and equipment, net $ 1,577 $ 2,018 Depreciation expense of Property and equipment, net totaled $658 and $726 for the years ended December 31, 2024 2023

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	7. Accrued liabilities consisted of the following: December 31, 2024 2023 Salaries, benefits and related expenses $ 1,684 $ 2,058 Device warranty 474 461 Other 194 145 Total $ 2,352 $ 2,664 Warranty Sales of devices generally include an initial warranty for parts and services for one two one three December 31, 2024 2023 Warranty 2024 2023 Balance at beginning of the period $ 566 $ 413 Additions for estimated future expense 730 619 Incurred costs (641 ) (466 ) Balance at end of the period $ 655 $ 566 Current portion $ 474 $ 461 Long-term portion 181 105 Total $ 655 $ 566

Note 8 - Goodwill and Intangibl

Note 8 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	8. On December 5, 2022, Goodwill The Company accounted for the acquisition as a business combination in accordance with ASC 805, The Company determined no December 31, 2024 2023. Intangible Assets The following table summarizes the components of gross intangible assets, accumulated amortization, and net carrying values for definite- and indefinite-lived intangible asset balances as of December 31, 2024 2023. December 31, 2024 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (598 ) $ 1,712 $ 2,310 $ (310 ) $ 2,000 Trade name 2,310 N/A 2,310 2,310 N/A 2,310 Intellectual property 460 (6 ) 454 460 — 460 Customer relationships 140 (36 ) 104 140 (18 ) 122 Below market lease — — — 20 (20 ) — Total intangible assets $ 5,220 $ (640 ) $ 4,580 $ 5,240 $ (348 ) $ 4,892 Definite-lived intangible assets are amortized over their estimated lives using the straight-line method, which is estimated as eight 12 eight no no December 31, 2024 2023. The estimated future amortization expenses related to definite-lived intangible assets as of December 31, 2024 Fiscal Year Amount 2025 $ 345 2026 345 2027 345 2028 345 Thereafter 890 Total $ 2,270 Amortization expense related to the acquired definite-lived intangible assets was $312 and $325 for the years ended December 31, 2024 2023,

Note 9 - Notes Payable, Net

Note 9 - Notes Payable, Net	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Long-Term Debt [Text Block]	9. BoC Term Loan In August 2020, 2024. first The Company was required to pay accrued interest on the current loan on the 13th August 13, 2023, August 17, 2023, August 13, 2026 prime rate 470, The BoC Loan Agreement contains a liquidity covenant, which requires that the Company maintain cash in accounts of the Lender or subject to control agreements in favor of the Lender in an amount equal to at least the outstanding balance of the BoC Term Loan, which was $2,000 as of December 31, 2024 December 31, 2024 The interest rate of the BoC Term Loan is subject to increase in the event of late payment and after occurrence of and during the continuation of an event of default. The Company may The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 8.55% and 8.81% for the years ended December 31, 2024 2023, December 31, 2024 2023 The following table presents scheduled principal payments of the Company's BoC Term Loan as of December 31, 2024 Period Amount 2026 $ 2,000 Total principal payments 2,000 Less debt discount and issuance costs (3 ) Note payable, net $ 1,997 Current portion $ — Long-term portion 1,997 Note payable, net $ 1,997 Parker Hannifin Promissory Note In connection with the HMC Acquisition, on December 5, 2022, December 31, 2023 September 30, 2027. The Promissory Note, upon the occurrence of an event of default, allows for the levying of interest equal to the lesser of (a) 5% per annum and (b) the maximum interest rate permitted under applicable law on the then entire outstanding principal balance, and also for the acceleration of all outstanding liabilities and obligations, making them immediately payable. Under the terms of the Promissory Note, the following occurrences constitute a default, and could, upon written notice or declaration by Parker, allow for the levying of interest and or the acceleration of principal outstanding: (i) failure to pay any amount of the principal when due and payable, (ii) the dissolution of the Company (including the declaration of bankruptcy), and (iii) the acquisition of the Company by another entity or the sale of substantially all of its assets to another entity. The Company recorded the Promissory Note of $4,055 in its consolidated balance sheets under the captions Notes payable, current and Notes payable, net, estimating an implicit discount rate of 7.5% via reference to the interest charged on the Company's BoC Term Loan and other relevant economic factors present at the execution date of the Promissory Note. The amortization of debt discounts resulted in an effective interest rate of 7.79% and 7.18% for the years ended December 31, 2024 2023, December 31, 2024 2023, The following table presents scheduled principal payments of the Promissory Note as of December 31, 2024 Period Amount 2025 $ 1,250 2026 1,250 2027 937 Total principal payments 3,437 Less debt discount (330 ) Note payable, net $ 3,107 Current portion 1,250 Long-term portion 1,857 Note payable, net $ 3,107

Note 10 - Lease Obligations

Note 10 - Lease Obligations	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. The Company's operating lease agreement for its headquarters and manufacturing facility in San Rafael, California (the "San Rafael Lease") commenced in July 2022 November 2026, three The San Rafael Lease constitutes an operating lease under ASC 842, July 2022 November 2026. three The Company's operating lease agreement for its office in Hamburg, Germany (the "Hamburg Lease") commenced in May 2022 June 2025, one five The Hamburg Lease constitutes a lease under ASC 842, May 2022 June 2025. five The Company's operating lease agreement for its shared service and manufacturing facility in Brecksville, Ohio (the "Ohio Lease") commenced in June 2024 July 2027, three July 2024, The Company has determined that the Ohio Lease constitutes an operating lease under ASC 842 July 2024 July 2027. three The Company’s future lease payments as of December 31, 2024 Operating Period Leases 2025 $ 481 2026 431 2027 41 Total lease payments 953 Less: imputed interest (74 ) Present value of lease liabilities $ 879 Lease liabilities, current $ 427 Lease liabilities 452 Total lease liabilities $ 879 Weighted-average remaining term (in years) 1.9 Weighted-average discount rate 8.4 % Lease expense under the Company’s operating leases was $588 and $548, for the years ended December 31, 2024 2023

Note 11 - Employee Benefit Plan

Note 11 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Retirement Benefits [Text Block]	11. The Company administers a 401 "401 may 401 401 December 31, 2024 2023, 401 December 31, 2024 2023. 401 December 31, 2024 2023

Note 12 - Capitalization and Eq

Note 12 - Capitalization and Equity Structure	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Equity [Text Block]	12. Summary The Company’s authorized capital stock as of December 31, 2024 December 31, 2024 Common Stock The holders of outstanding shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board of Directors may one no not not September 2024 On August 29, 2024, "September 2024 September 2024 September 3, 2024. September 2024 September 2024 January 2024 On January 10, 2024, “January 2024 January 2024 January 2024 At the Market Offering In October 2020, may may 415 may 3 No. 333 272607 June 20, 2023, July 28, 2023 ( may may June 2023, may not December 31, 2024 December 31, 2023, December 31, 2024 Preferred Stock The Company may one no may Warrants Warrants outstanding as of December 31, 2024 December 31, 2023 Exercise Remaining term Source Price (Years) December 31, 2023 Issued Expired Exercised December 31, 2024 September 2024 Pre-Funded Warrants $ 0.001 * — 2,900 — (335 ) 2,565 September 2024 Series A Warrants $ 1.00 4.7 — 6,000 — — 6,000 September 2024 Series B Warrants $ 1.00 0.7 — 6,000 — — 6,000 2021 Warrants $ 12.81 1.1 273 — — — 273 June 2020 Investor Warrants $ 5.18 0.9 127 — — — 127 June 2020 Placement Agent Warrants $ 5.64 0.4 39 — — — 39 December 2019 Warrants $ 8.10 0.5 556 — — — 556 December 2019 Placement Agent Warrants $ 8.44 0.0 52 — (52 ) — — May 2019 Warrants $ 1.55 0.0 193 — (193 ) — — 1,240 14,900 (245 ) (335 ) 15,560 (*) The September 2024 not 335 warrants were exercised during the year ended December 31, 2024 2023 December 31, 2024 September 2024 In September 2024, September 2024 not In September 2024, September 4, 2029. In September 2024, 6,000 September 3, 2025. The Pre-Funded Warrant, the Series A Warrants, and the Series B Warrants (collectively, the “September 2024 may not not September 2024 not September 2024 may not 61st In the event the Company enters into a Fundamental Transaction, as defined in the applicable September 2024 September 2024 may not not not The September 2024 September 2024 September 2024 not September 2024 not 2021 In February 2021, 2021 2021 February 11, 2026. 2021 may not not 2021 not 2021 may not 61st The 2021 2021 2021 2021 30 2021 2021 five 2021 The warrant liability related to the 2021 3 2021 December 31, 2024 December 31, 2023 Current share price $ 0.61 $ 2.50 Conversion price $ 12.81 $ 12.81 Risk-free interest rate 3.94 % 4.20 % Expected term (years) 1.11 2.11 Volatility of stock 106.7 % 76.5 % June 2020 In June 2020, "June 2020 June 2020 December 10, 2025. June 2020 may not not June 2020 not June 2020 may not 61st The June 2020 June 2020 June 2020 June 2020 June 2020 June 2020 June 2020 30 June 2020 June 2020 June 2020 The warrant liability related to the June 2020 3 June 2020 December 31, 2024 December 31, 2023 Current share price $ 0.61 $ 2.50 Conversion price $ 5.18 $ 5.18 Risk-free interest rate 4.03 % 4.26 % Expected term (years) 0.94 1.94 Volatility of stock 89.7 % 78.2 % June 2020 In June 2020, "June 2020 June 2020 June 2020 June 7, 2025. Because of the put-option provision in the June 2020 The warrant liability related to the June 2020 3 June 2020 December 31, 2024 December 31, 2023 Current share price $ 0.61 $ 2.50 Conversion price $ 5.64 $ 5.64 Risk-free interest rate 4.47 % 4.54 % Expected term (years) 0.44 1.44 Volatility of stock 89.7 % 83.0 % December 2019 In December 2019, "December 2019 "December 2019 December 2019 June 21, 2025. December 2019 may not not December 2019 not December 2019 may not 61st The December 2019 December 2019 December 2019 December 2019 December 2019 December 2019 December 2019 30 December 2019 December 2019 five December 2019 The warrant liability related to the December 2019 3 December 2019 December 31, 2024 December 31, 2023 Current share price $ 0.61 $ 2.50 Conversion price $ 8.10 $ 8.10 Risk-free interest rate 4.43 % 4.53 % Expected term (years) 0.46 1.47 Volatility of stock 89.3 % 82.3 % December 2019 In December 2019, December 2019 "December 2019 December 2019 December 2019 December 18, 2024. The warrant liability related to the December 2019 3 December 2019 December 31, 2024 December 31, 2023 Current share price N/A $ 2.50 Conversion price N/A $ 8.44 Risk-free interest rate N/A 4.82 % Expected term (years) — 0.97 Volatility of stock N/A 85.2 % May 2019 In May 2019, "May 2019 "May 2019 May 2019 five May 2024. The warrant liability related to the May 2019 3 May 2019 May 2019 December 31, 2024 December 31, 2023 Current share price N/A $ 1.88 Conversion price N/A $ 3.52 Risk-free interest rate N/A 5.28 % Expected term (years) — 0.40 Volatility of stock N/A 77.5 % ( 1 December 31, 2023, first 2024, by 25%

Note 13 - Stock-based Compensat

Note 13 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	13. 2014 In 2014, 2014 "2014 January 31, 2024. 2024 no 2014 June 6, 2024, 2014 2014 2014 April 15, 2034, 2014 December 31, 2024 2014 Original share pool 137 2015 increase 111 2017 increase 67 December 2017 increase (ratified in June 2018) 293 2019 increase 233 March 2020 increase 333 December 2020 increase 800 2022 increase 550 2023 increase 1,200 2024 increase 1,000 Total shares authorized for grant as of December 31, 2024 4,724 Under the terms of the Restated 2014 may one Shares available for future grant as of December 31, 2024 2014 Shares Available For Grant Available as of December 31, 2023 277 Share pool increase 1,000 Granted (703 ) Forfeited 49 Expired 69 Available as of December 31, 2024 692 Restricted Stock Units The Company issues time-based RSUs and PSUs to employees and non-employees. Each RSU and PSU represents the right to receive one Combined RSU and PSU activity for the year ended December 31, 2024 Weighted Number of Average Grant- Shares Date Fair Value Unvested as of December 31, 2023 1,305 $ 1.67 Granted 703 $ 1.08 Vested (934 ) $ 1.75 Forfeited (49 ) $ 1.76 Unvested as of December 31, 2024 1,025 $ 1.22 The total grant-date fair value of RSUs and PSUs that vested during the year ended December 31, 2024 December 31, 2024 Stock Options The Board of Directors may 2014 not may not ten 2014 2014 four may A summary of the stock option activity during the year ended December 31, 2024 Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life (Years) Value Outstanding at beginning of year 251 $ 36.19 Forfeited — $ — Expired (68 ) $ 48.61 Outstanding at end of year 183 $ 31.53 3.59 $ — Vested and expected to vest 183 $ 31.53 3.58 $ — Exercisable at year end 183 $ 31.53 3.59 $ — No stock options were exercised during the years ended December 31, 2024 2023 As no stock options were granted during the years ended December 31, 2024 December 31, 2023 December 31, 2024 2023 As of December 31, 2024 The following table summarizes information about stock options outstanding as of December 31, 2024 Options Outstanding Options Exercisable Weighted-Average Range of Remaining Weighted Weighted Exercise Number of Contractual Life Average Number of Average Prices Shares (Years) Price Shares Price $5.55 - $5.70 47 5.05 $ 5.69 47 $ 5.69 $9.15 - $26.39 62 3.95 $ 16.88 62 $ 16.86 $26.85 - $54.15 47 3.32 $ 31.69 47 $ 31.71 $60.00 - $196.35 27 1.03 $ 108.43 27 $ 108.43 183 3.63 $ 31.53 183 $ 31.53 Compensation Expense Stock-based compensation is included in the consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending on the nature of services provided. Stock-based compensation expense related to RSUs and PSUs was recorded as follows: Years Ended December 31, 2024 2023 Sales and marketing $ 98 $ 260 Research and development 220 423 General and administrative 1,055 1,175 $ 1,373 $ 1,858 Employee Stock Purchase Plan The Company has an Employee Stock Purchase Plan ("ESPP"). Under the ESPP, the Company has 33 shares of common stock reserved for issuance, subject to adjustment in the event of a stock split, stock dividend, combination, reclassification or similar event. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 25% of their eligible compensation, subject to any plan limitations. The ESPP provides for six first December 31, 2024 not

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. The domestic and foreign components of pre-tax loss for the years ended December 31, 2024 2023 Years Ended December 31, 2024 2023 Domestic $ (11,576 ) $ (13,521 ) Foreign 246 (1,677 ) Loss before income taxes $ (11,330 ) $ (15,198 ) The Company had no current or deferred federal and state income tax expense or benefit for the years ended December 31, 2024 2023 not not December 31, 2024 2023, December 31, 2024 2023 Years Ended December 31, 2024 2023 Federal tax at statutory rate 21.0 % 21.0 % State tax, net of federal tax effect — — Research and development credit (0.1 ) 1.1 Change in valuation allowance (13.5 ) (12.5 ) Unrealized gain on warrant 0.7 (0.2 ) Stock-based compensation (4.7 ) (1.7 ) Other (2.8 ) (0.7 ) Foreign (0.6 ) (7.0 ) Total tax expense (benefit) — % — % The tax effects of temporary differences and related deferred tax assets and liabilities as of December 31, 2024 2023 December 31, 2024 2023 Deferred tax assets: Depreciation and other $ 119 $ 136 Net operating loss carryforwards 54,001 52,448 Research and development tax credits 2,210 2,219 Accruals and reserves 235 311 Capitalized research and development costs 1,817 1,422 Deferred revenue 400 220 Stock compensation expense 1,028 1,493 Lease assets 154 178 Other 48 50 Deferred tax liabilities: Lease liabilities (133 ) (152 ) Prepaid expenses (54 ) (56 ) Less: Valuation allowance (59,825 ) (58,269 ) Net deferred tax asset (liability) $ — $ — The Company’s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of the Company’s net deferred tax assets. The Company primarily considered such factors as the Company’s history of operating losses, the nature of the Company’s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. The Company does not not no December 31, 2024 2023, 2017 174 December 31, 2021. December 31, 2024 2023, December 31, 2024, January 1, 2018 2027, 80% 2031, not As of December 31, 2024, 2025. no December 31, 2024, not may 382 December 31, 2024 2023, Years Ended December 31, 2024 2023 Beginning balances as of January 1, 2024 and 2023 $ 1,894 $ 716 (Decrease) increase of unrecognized tax benefits taken in prior years (58 ) 9 Increase of unrecognized tax benefits related to current year — 1,169 Ending balances as of December 31, 2024 and 2023 $ 1,836 $ 1,894 If the Company is able to recognize these uncertain tax positions, the unrecognized tax benefits would not not December 31, 2024. not 12 no 2007 2024 three four 2019 2024 four 2024 four

Note 15 - Commitments and Conti

Note 15 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	15. Commitments Material Contracts The Company has two The Company has two Under the Vanderbilt Exoskeleton License Agreement, the Company is required to pay 6% of net sales of licensed patent products and 3% of net sales of licensed software products. The minimum annual royalty for licensed products is $250. The Vanderbilt Exoskeleton License Agreement will continue until April 29, 2038, Under the Vanderbilt Knee License Agreement, the Company is required to pay 3.75% of net sales for licensed patent products and the minimum annual royalty is $75 due on or before July 31, 2028 February 15, 2041, Purchase Obligations The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling $1,263 as of December 31, 2024 one December 31, 2023. may The Company has operating lease commitments totaling $953 payable over the lease terms of the San Rafael Lease, the Ohio Lease and the Hamburg Lease as disclosed in Note 10. Lease Obligations Other Contractual Obligations The following table summarizes the Company's outstanding contractual obligations, including interest payments, as of December 31, 2024 Payments Due By Period Less than Total one year 1-3 Years Term loan $ 2,260 $ 156 $ 2,104 Promissory note 3,437 1,250 2,187 Facility operating leases 953 481 472 Total $ 6,650 $ 1,887 $ 4,763 Loss Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not

Note 16 - Segment Disclosures

Note 16 - Segment Disclosures	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	16. Operating segments are defined as components of a public entity for which discrete financial information is available and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company's CODM is its chief executive officer who reviews financial information, annual operating plans, and long-range forecasts, presented on a consolidated basis, for purposes of making operating decisions, evaluating financial performance, and allocating resources. The Company is managed as a single operating segment that primarily serves people with physical disabilities or impairments in both physical rehabilitation and mobility in the healthcare market. Managing the Company's business activities on a consolidated basis allows the Company to benefit from the value its healthcare products provide across the care continuum. The Company’s CODM uses net loss as presented on the consolidated statements of operations and comprehensive loss to measure segment loss and assesses financial performance against expectations for the Company's single reportable segment to decide how to allocate resources. Additionally, the CODM reviews and uses segment expenses included in net loss to manage the Company’s operations and assess operating performance. The measure of segment assets is reported on the Company's consolidated balance sheets as total assets. The significant segment expenses regularly provided to the CODM are those presented on the consolidated statements of operations and comprehensive loss. These significant segment expenses include cost of revenue, sales and marketing, research and development and general and administrative expenses. Other segment items that are presented on the consolidated statements of operations and comprehensive loss include interest expense, net, gain (loss) on revaluation of warrant liabilities, loss on modification of warrant, unrealized (loss) gain on foreign exchange and other expense, net. The Company’s entity-wide disclosures, including the breakout of revenue by major source and geographies, are included in Note 5. Revenue

Note 17 - Related Party Transac

Note 17 - Related Party Transactions	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	17. On February 4, 2023, July 2017. one two The total settlement amount was $325 and paid in cash over 14 first April 2024. December 31, 2024 2023,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of Presentation and Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). The consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications For the year ended December 31, 2024, one 6. Property and Equipment, net
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying consolidated statements of operations and comprehensive loss.
Comprehensive Income, Policy [Policy Text Block]	Accumulated Other Comprehensive Income The Company's accumulated other comprehensive income consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income presented on the consolidated balance sheets for the year ended December 31, 2024 2023, Accumulated Other Comprehensive Income Balance as of December 31, 2022 $ 563 Net unrealized loss on foreign currency translation (407 ) Balance as of December 31, 2023 156 Net unrealized gain on foreign currency translation 801 Balance as of December 31, 2024 $ 957
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company's cash balances held in domestic banks are deposited into accounts at various financial institutions with each balance under the $250 $100 two The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not not The Company had two 10% December 31, 2024 December 31, 2023 The Company had one customer with sales of 10% December 31, 2024 2023
Accounts Receivable [Policy Text Block]	Accounts Receivable and Allowance for Credit Losses The Company carries accounts receivable at invoiced amounts less an allowance (or "provision") for credit losses. The Company reviews accounts receivables for collectability and determines an allowance for credit losses. The allowance for credit losses on accounts receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on historical bad debt expense, the aging of the accounts, known troubled accounts, customer payment history, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 90 not December 31, 2024 2023 December 31, 2024 2023, 2022
Inventory, Policy [Policy Text Block]	Inventories Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first first Inventories consisted of the following: December 31, 2024 2023 Raw materials $ 3,551 $ 4,298 Work in progress 177 290 Finished goods 843 462 Inventories $ 4,571 $ 5,050
Lessee, Leases [Policy Text Block]	Leases The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases not may Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. Leases with an initial term of 12 not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally ranging from three 10 The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not None December 31, 2024 2023 December 31, 2024 2023
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. The Company performs an annual impairment assessment, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill. Such indicators include, among others, material departures from projected sales volume, deteriorating gross margins, and uncertainties regarding continued commercialization as a result of changing business strategies. The Company determined no impairment existed for the years ended December 31, 2024 December 31, 2023
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Other intangible assets include developed technology, acquired intellectual property, and customer relationships, in the case of finite-lived intangibles, and trade names in the case of indefinite-lived intangibles. Finite-lived intangibles are amortized over their estimated useful lives and are tested for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of the assets may not The Company determined no impairment existed for the year ended December 31, 2024 December 31, 2023
Warrant Valuation [Policy Text Block]	Warrant Valuation The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that it may Where there is a possibility that the Company may
Going Concern [Policy Text Block]	Going Concern The Company assesses its ability to continue as a going concern in accordance with ASC 205 40, Presentation of Financial Statements Going Concern
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers five For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not The Company generally does not not December 31, 2024 2023, not not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs consist of costs incurred for internal research and development activities. These costs primarily include salaries and other personnel-related expenses, contractor fees, prototype materials, facility costs, supplies, and depreciation of equipment associated with the design and development of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have not not
Share-Based Payment Arrangement [Policy Text Block]	Stock-based Compensation The Company measures stock-based compensation expense for restricted stock units (“RSUs”) and performance stock units ("PSUs") made to employees and directors based on the Company’s closing stock price on the date of grant and recognizes the value on a straight-line basis over the requisite service periods of the awards. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For awards with performance-based conditions, at the point that it becomes probable that the performance conditions will be met, the Company records a cumulative catch-up of the expense from the grant date to the current date, and then amortizes the remainder of the expense over the remaining service period. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur. The Company measures stock-based compensation expense for stock options granted to employees and directors based on the estimated fair value of the award on the date of grant and recognizes the fair value on a straight-line basis over the requisite service periods of the awards. The Company determines the fair value of stock options on the date of grant using the Black-Scholes Model, which is affected by the Company’s stock price and assumptions regarding a number of subjective variables. These variables include, but are not 14. The Company has, from time to time, modified the terms of its stock options and RSUs to certain employees and directors. The Company accounts for the incremental compensation cost, which is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification, as an expense for vested awards or over the remaining service (vesting) period for unvested awards.
New Accounting Pronouncements, Policy [Policy Text Block]	Accounting Pronouncements Adopted in 2024 November 2023, No. 2023 07, 280 2023 07" 2023 07 2023 07 December 15, 2023, December 15, 2024. 10 December 31, 2024. not 16. Segment Disclosures Recent Accounting Pronouncements In December 2023, No. 2023 09, 740 2023 09" 2023 09 December 15, 2024, not 2023 09 In November 2024, No. 2024 03, 220 40 2024 03” December 15, 2026, December 15, 2027,

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies and Estimates (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated Other Comprehensive Income Balance as of December 31, 2022 $ 563 Net unrealized loss on foreign currency translation (407 ) Balance as of December 31, 2023 156 Net unrealized gain on foreign currency translation 801 Balance as of December 31, 2024 $ 957
Schedule of Inventory, Current [Table Text Block]	December 31, 2024 2023 Raw materials $ 3,551 $ 4,298 Work in progress 177 290 Finished goods 843 462 Inventories $ 4,571 $ 5,050

Note 3 - Net Loss Per Share o_2

Note 3 - Net Loss Per Share of Common Stock (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years ended December 31, 2024 2023 Numerator Adjusted net loss used for dilution calculation $ (11,330 ) $ (15,198 ) Denominator Weighted-average number of shares outstanding (1) 20,161 13,867 Effect of potential dilutive shares — — Dilutive weighted-average number of shares outstanding 20,161 13,867 Net loss per share, basic and diluted $ (0.56 ) $ (1.10 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Years ended December 31, 2024 2023 Options to purchase common stock 183 252 Restricted stock units 1,025 1,305 Warrants for common stock (1) 12,995 1,240 Total common stock equivalents 14,203 2,797

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total Level 1 Level 2 Level 3 December 31, 2024 Liabilities Warrant liabilities $ 1 $ — $ — $ 1 December 31, 2023 Liabilities Warrant liabilities $ 366 $ — $ — $ 366
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant Liability Balance as of December 31, 2022 $ 233 Loss on revaluation of warrants issued in 2021, June 2020, December 2019, and May 2019 equity financings 133 Balance as of December 31, 2023 $ 366 Gain on revaluation of warrants issued in 2021, June 2020, December 2019, and May 2019 equity financings $ (474 ) Loss on modification of warrant 109 Balance as of December 31, 2024 $ 1

Note 5 - Revenue (Tables)

Note 5 - Revenue (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	December 31, 2024 December 31, 2023 Deferred extended maintenance and support $ 3,669 $ 3,993 Deferred device and advances 207 169 Total deferred revenues 3,876 4,162 Less current portion (1,956 ) (1,993 ) Deferred revenues, non-current $ 1,920 $ 2,169 Year Ended December 31, 2024 Year Ended December 31, 2023 Beginning balance $ 4,162 $ 2,153 Deferral of revenue 3,331 4,727 Recognition of deferred revenue (3,617 ) (2,718 ) Ending balance $ 3,876 $ 4,162
Disaggregation of Revenue [Table Text Block]	Total Device revenue $ 13,323 Service and support 3,121 Subscriptions 527 Parts and other 954 $ 17,925 Total Device revenue $ 14,132 Service and support 2,821 Subscriptions 967 Parts and other 359 $ 18,279
Revenue from External Customers by Geographic Areas [Table Text Block]	Year ended December 31, 2024 2023 United States $ 9,712 $ 12,500 Other 421 495 Americas 10,133 12,995 France 3,006 181 Other 2,936 3,584 EMEA 5,942 3,765 APAC 1,850 1,519 $ 17,925 $ 18,279

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	Estimated December 31, Life (Years) 2024 2023 Company-owned device fleet 1-5 $ 2,572 $ 2,828 Molds and other tools 5-7 1,424 1,418 Machinery and equipment 3-7 380 401 Software 3-5 234 234 Leasehold improvement 1-3 194 178 Furniture and office equipment 3-7 114 114 4,918 5,174 Accumulated depreciation and amortization (3,341 ) (3,156 ) Property and equipment, net $ 1,577 $ 2,018

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2024 2023 Salaries, benefits and related expenses $ 1,684 $ 2,058 Device warranty 474 461 Other 194 145 Total $ 2,352 $ 2,664
Product Maintenance And Warranty [Table Text Block]	Warranty 2024 2023 Balance at beginning of the period $ 566 $ 413 Additions for estimated future expense 730 619 Incurred costs (641 ) (466 ) Balance at end of the period $ 655 $ 566 Current portion $ 474 $ 461 Long-term portion 181 105 Total $ 655 $ 566

Note 8 - Goodwill and Intangi_2

Note 8 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2024 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (598 ) $ 1,712 $ 2,310 $ (310 ) $ 2,000 Trade name 2,310 N/A 2,310 2,310 N/A 2,310 Intellectual property 460 (6 ) 454 460 — 460 Customer relationships 140 (36 ) 104 140 (18 ) 122 Below market lease — — — 20 (20 ) — Total intangible assets $ 5,220 $ (640 ) $ 4,580 $ 5,240 $ (348 ) $ 4,892
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Fiscal Year Amount 2025 $ 345 2026 345 2027 345 2028 345 Thereafter 890 Total $ 2,270

Note 9 - Notes Payable, Net (Ta

Note 9 - Notes Payable, Net (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Maturities of Long-Term Debt [Table Text Block]	Period Amount 2026 $ 2,000 Total principal payments 2,000 Less debt discount and issuance costs (3 ) Note payable, net $ 1,997 Current portion $ — Long-term portion 1,997 Note payable, net $ 1,997 Period Amount 2025 $ 1,250 2026 1,250 2027 937 Total principal payments 3,437 Less debt discount (330 ) Note payable, net $ 3,107 Current portion 1,250 Long-term portion 1,857 Note payable, net $ 3,107

Note 10 - Lease Obligations (Ta

Note 10 - Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Operating Period Leases 2025 $ 481 2026 431 2027 41 Total lease payments 953 Less: imputed interest (74 ) Present value of lease liabilities $ 879 Lease liabilities, current $ 427 Lease liabilities 452 Total lease liabilities $ 879 Weighted-average remaining term (in years) 1.9 Weighted-average discount rate 8.4 %

Note 12 - Capitalization and _2

Note 12 - Capitalization and Equity Structure (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Remaining term Source Price (Years) December 31, 2023 Issued Expired Exercised December 31, 2024 September 2024 Pre-Funded Warrants $ 0.001 * — 2,900 — (335 ) 2,565 September 2024 Series A Warrants $ 1.00 4.7 — 6,000 — — 6,000 September 2024 Series B Warrants $ 1.00 0.7 — 6,000 — — 6,000 2021 Warrants $ 12.81 1.1 273 — — — 273 June 2020 Investor Warrants $ 5.18 0.9 127 — — — 127 June 2020 Placement Agent Warrants $ 5.64 0.4 39 — — — 39 December 2019 Warrants $ 8.10 0.5 556 — — — 556 December 2019 Placement Agent Warrants $ 8.44 0.0 52 — (52 ) — — May 2019 Warrants $ 1.55 0.0 193 — (193 ) — — 1,240 14,900 (245 ) (335 ) 15,560
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	December 31, 2024 December 31, 2023 Current share price $ 0.61 $ 2.50 Conversion price $ 12.81 $ 12.81 Risk-free interest rate 3.94 % 4.20 % Expected term (years) 1.11 2.11 Volatility of stock 106.7 % 76.5 % December 31, 2024 December 31, 2023 Current share price $ 0.61 $ 2.50 Conversion price $ 5.18 $ 5.18 Risk-free interest rate 4.03 % 4.26 % Expected term (years) 0.94 1.94 Volatility of stock 89.7 % 78.2 % December 31, 2024 December 31, 2023 Current share price $ 0.61 $ 2.50 Conversion price $ 5.64 $ 5.64 Risk-free interest rate 4.47 % 4.54 % Expected term (years) 0.44 1.44 Volatility of stock 89.7 % 83.0 % December 31, 2024 December 31, 2023 Current share price $ 0.61 $ 2.50 Conversion price $ 8.10 $ 8.10 Risk-free interest rate 4.43 % 4.53 % Expected term (years) 0.46 1.47 Volatility of stock 89.3 % 82.3 % December 31, 2024 December 31, 2023 Current share price N/A $ 2.50 Conversion price N/A $ 8.44 Risk-free interest rate N/A 4.82 % Expected term (years) — 0.97 Volatility of stock N/A 85.2 % December 31, 2024 December 31, 2023 Current share price N/A $ 1.88 Conversion price N/A $ 3.52 Risk-free interest rate N/A 5.28 % Expected term (years) — 0.40 Volatility of stock N/A 77.5 %

Note 13 - Stock-based Compens_2

Note 13 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Share-Based Payment Arrangement, Activity [Table Text Block]	Original share pool 137 2015 increase 111 2017 increase 67 December 2017 increase (ratified in June 2018) 293 2019 increase 233 March 2020 increase 333 December 2020 increase 800 2022 increase 550 2023 increase 1,200 2024 increase 1,000 Total shares authorized for grant as of December 31, 2024 4,724 Shares Available For Grant Available as of December 31, 2023 277 Share pool increase 1,000 Granted (703 ) Forfeited 49 Expired 69 Available as of December 31, 2024 692
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]	Weighted Number of Average Grant- Shares Date Fair Value Unvested as of December 31, 2023 1,305 $ 1.67 Granted 703 $ 1.08 Vested (934 ) $ 1.75 Forfeited (49 ) $ 1.76 Unvested as of December 31, 2024 1,025 $ 1.22
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life (Years) Value Outstanding at beginning of year 251 $ 36.19 Forfeited — $ — Expired (68 ) $ 48.61 Outstanding at end of year 183 $ 31.53 3.59 $ — Vested and expected to vest 183 $ 31.53 3.58 $ — Exercisable at year end 183 $ 31.53 3.59 $ —
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted-Average Range of Remaining Weighted Weighted Exercise Number of Contractual Life Average Number of Average Prices Shares (Years) Price Shares Price $5.55 - $5.70 47 5.05 $ 5.69 47 $ 5.69 $9.15 - $26.39 62 3.95 $ 16.88 62 $ 16.86 $26.85 - $54.15 47 3.32 $ 31.69 47 $ 31.71 $60.00 - $196.35 27 1.03 $ 108.43 27 $ 108.43 183 3.63 $ 31.53 183 $ 31.53
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Years Ended December 31, 2024 2023 Sales and marketing $ 98 $ 260 Research and development 220 423 General and administrative 1,055 1,175 $ 1,373 $ 1,858

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Years Ended December 31, 2024 2023 Domestic $ (11,576 ) $ (13,521 ) Foreign 246 (1,677 ) Loss before income taxes $ (11,330 ) $ (15,198 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Years Ended December 31, 2024 2023 Federal tax at statutory rate 21.0 % 21.0 % State tax, net of federal tax effect — — Research and development credit (0.1 ) 1.1 Change in valuation allowance (13.5 ) (12.5 ) Unrealized gain on warrant 0.7 (0.2 ) Stock-based compensation (4.7 ) (1.7 ) Other (2.8 ) (0.7 ) Foreign (0.6 ) (7.0 ) Total tax expense (benefit) — % — %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2024 2023 Deferred tax assets: Depreciation and other $ 119 $ 136 Net operating loss carryforwards 54,001 52,448 Research and development tax credits 2,210 2,219 Accruals and reserves 235 311 Capitalized research and development costs 1,817 1,422 Deferred revenue 400 220 Stock compensation expense 1,028 1,493 Lease assets 154 178 Other 48 50 Deferred tax liabilities: Lease liabilities (133 ) (152 ) Prepaid expenses (54 ) (56 ) Less: Valuation allowance (59,825 ) (58,269 ) Net deferred tax asset (liability) $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Years Ended December 31, 2024 2023 Beginning balances as of January 1, 2024 and 2023 $ 1,894 $ 716 (Decrease) increase of unrecognized tax benefits taken in prior years (58 ) 9 Increase of unrecognized tax benefits related to current year — 1,169 Ending balances as of December 31, 2024 and 2023 $ 1,836 $ 1,894

Note 15 - Commitments and Con_2

Note 15 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Contractual Obligation, Fiscal Year Maturity [Table Text Block]	Payments Due By Period Less than Total one year 1-3 Years Term loan $ 2,260 $ 156 $ 2,104 Promissory note 3,437 1,250 2,187 Facility operating leases 953 481 472 Total $ 6,650 $ 1,887 $ 4,763

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Retained Earnings (Accumulated Deficit)	$ (250,475)	$ (239,145)
Net Cash Provided by (Used in) Operating Activities	(9,846)	$ (12,054)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	6,493
Debt Covenant, Covenant Compliance, Unrestricted Cash	2,000
Unrestricted Cash	$ 4,493

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies and Estimates (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Accounts Receivable, after Allowance for Credit Loss, Current	$ 7,238	$ 5,645	$ 4,625
Tangible Asset Impairment Charges	0	0
Goodwill, Impairment Loss	0	0
Impairment of Intangible Assets (Excluding Goodwill)	$ 0	$ 0
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	10 years
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number Of Customers	2	0
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number Of Customers	1	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer A [Member]
Concentration Risk, Percentage	17%	15%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies and Estimates - Schedule of Accumulated Other Comprehensive Gain (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Balance	$ 12,606	$ 25,442
Balance	12,707	12,606
AOCI Attributable to Parent [Member]
Balance	156	563
Net unrealized loss on foreign currency translation	801	(407)
Balance	$ 957	$ 156

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies and Estimates - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Raw materials	$ 3,551	$ 4,298
Work in progress	177	290
Finished goods	843	462
Inventories	$ 4,571	$ 5,050

Note 3 - Net Loss Per Share o_3

Note 3 - Net Loss Per Share of Common Stock (Details Textual)	12 Months Ended
	Dec. 31, 2024 shares
Class Of Warrant Or Right, Issued (in shares)	14,900,000
Pre-Funded Warrants [Member]
Class Of Warrant Or Right, Issued (in shares)	2,900

Note 3 - Net Loss Per Share o_4

Note 3 - Net Loss Per Share of Common Stock - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Adjusted net loss used for dilution calculation		$ (11,330)	$ (15,198)
Weighted average number of shares outstanding, basic and diluted (in shares)	[1]	20,161	13,867
Effect of potential dilutive shares (in shares)		0	0
Dilutive weighted-average number of shares outstanding (in shares)		20,161	13,867
Net loss per share, basic and diluted (in dollars per share)		$ (0.56)	$ (1.1)
[1]Includes the weighted average effect of the Pre-Funded Warrant, the exercise of which requires nominal consideration for the delivery of the shares of common stock.

Note 3 - Net Loss Per Share o_5

Note 3 - Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities (Details) - shares shares in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Antidilutive Securities (in shares)		14,203	2,797
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)		183	252
Restricted Stock [Member]
Antidilutive Securities (in shares)		1,025	1,305
Warrant [Member]
Antidilutive Securities (in shares)	[1]	12,995	1,240
[1]Represents the number of shares of common stock underlying our outstanding warrants as of such dates, except for the 2,900 shares of common stock underlying the Pre-Funded Warrant issued during the year ended December 31, 2024. The weighted average number of common shares outstanding, used in the basic and diluted Net loss per share as of December 31, 2024, includes the weighted average effect of the Pre-Funded Warrant issued in connection with the September 2024 firm commitment underwritten public offering, the exercise of which requires nominal consideration for the delivery of the shares of common stock. Refer to Note 12. Capitalization and Equity Structure — Warrants for additional information regarding the warrants.

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurement - Fair Value Hierarchies (Details) - Fair Value, Recurring [Member] - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Warrant liabilities	$ 1	$ 366
Fair Value, Inputs, Level 1 [Member]
Warrant liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Warrant liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Warrant liabilities	$ 1	$ 366

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurement - Changes in Fair Value (Details) - Derivative Financial Instruments, Liabilities [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Balance	$ 366	$ 233
Loss on revaluation of warrants issued in 2021, June 2020, December 2019, and May 2019 equity financings	(474)	133
Loss on modification of warrant	109
Balance	$ 1	$ 366

Note 5 - Revenue 1 (Details Tex

Note 5 - Revenue 1 (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Sep. 25, 2023
Contract With Customer, Liability, Non-Cancellable Backlog	$ 3,364
Product and Service, Other [Member]
Contract With Customer, Liability, Non-Cancellable Backlog	2,951
Subscription [Member]
Contract With Customer, Liability, Non-Cancellable Backlog	$ 413
Parker [Member]
Deferred Revenue, Warranty Claim Lump Sum		$ 700
Minimum [Member] | Ekso Health [Member]
Contracts With Customer, Accounts Receivable, Payment Terms, Duration (Month)	12 months
Maximum [Member] | Ekso Health [Member]
Contracts With Customer, Accounts Receivable, Payment Terms, Duration (Month)	48 months

Note 5 - Revenue 2 (Details Tex

Note 5 - Revenue 2 (Details Textual) $ in Thousands	Dec. 31, 2024 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1,956
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1,023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Amount	$ 897
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year

Note 5 - Revenue - Deferred Rev

Note 5 - Revenue - Deferred Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Deferred extended maintenance and support	$ 3,669	$ 3,993
Deferred device and advances	207	169
Total deferred revenues	3,876	4,162
Less current portion	(1,956)	(1,993)
Deferred revenues, non-current	1,920	2,169
Beginning balance	4,162	2,153
Deferral of revenue	3,331	4,727
Recognition of deferred revenue	(3,617)	(2,718)
Ending balance	$ 3,876	$ 4,162

Note 5 - Revenue - Disaggregati

Note 5 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenue	$ 17,925	$ 18,279
Ekso Health [Member]
Revenue	17,925
Product [Member] | Ekso Health [Member]
Revenue	13,323	14,132
Service [Member] | Ekso Health [Member]
Revenue	3,121	2,821
Subscription [Member] | Ekso Health [Member]
Revenue	527	967
Product and Service, Other [Member] | Ekso Health [Member]
Revenue	$ 954	$ 359

Note 5 - Revenue - Geographic I

Note 5 - Revenue - Geographic Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenue	$ 17,925	$ 18,279
UNITED STATES
Revenue	9,712	12,500
Americas Other [Member]
Revenue	421	495
Americas [Member]
Revenue	10,133	12,995
FRANCE
Revenue	3,006	181
Other Country [Member]
Revenue	2,936	3,584
EMEA [Member]
Revenue	5,942	3,765
Asia Pacific [Member]
Revenue	$ 1,850	$ 1,519

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Depreciation	$ 658	$ 726

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property and equipment, gross	$ 4,918	$ 5,174
Accumulated depreciation and amortization	(3,341)	(3,156)
Property and equipment, net	$ 1,577	2,018
Minimum [Member]
Property and equipment, useful life (Year)	3 years
Maximum [Member]
Property and equipment, useful life (Year)	10 years
Transportation Equipment [Member]
Property and equipment, gross	$ 2,572	2,828
Transportation Equipment [Member] | Minimum [Member]
Property and equipment, useful life (Year)	1 year
Transportation Equipment [Member] | Maximum [Member]
Property and equipment, useful life (Year)	5 years
Tools, Dies and Molds [Member]
Property and equipment, gross	$ 1,424	1,418
Tools, Dies and Molds [Member] | Minimum [Member]
Property and equipment, useful life (Year)	5 years
Tools, Dies and Molds [Member] | Maximum [Member]
Property and equipment, useful life (Year)	7 years
Machinery and Equipment [Member]
Property and equipment, gross	$ 380	401
Machinery and Equipment [Member] | Minimum [Member]
Property and equipment, useful life (Year)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property and equipment, useful life (Year)	7 years
Software and Software Development Costs [Member]
Property and equipment, gross	$ 234	234
Software and Software Development Costs [Member] | Minimum [Member]
Property and equipment, useful life (Year)	3 years
Software and Software Development Costs [Member] | Maximum [Member]
Property and equipment, useful life (Year)	5 years
Leasehold Improvements [Member]
Property and equipment, gross	$ 194	178
Leasehold Improvements [Member] | Minimum [Member]
Property and equipment, useful life (Year)	1 year
Leasehold Improvements [Member] | Maximum [Member]
Property and equipment, useful life (Year)	3 years
Furniture and Fixtures [Member]
Property and equipment, gross	$ 114	$ 114
Furniture and Fixtures [Member] | Minimum [Member]
Property and equipment, useful life (Year)	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property and equipment, useful life (Year)	7 years

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Salaries, benefits and related expenses	$ 1,684	$ 2,058
Device warranty	474	461
Other	194	145
Total	$ 2,352	$ 2,664

Note 7 - Accrued Liabilities _2

Note 7 - Accrued Liabilities - Warrant Liability (Details) - Warranty [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Balance at beginning of the period	$ 566	$ 413
Additions for estimated future expense	730	619
Incurred costs	(641)	(466)
Balance at end of the period	655	566
Current portion	474	461
Long-term portion	181	105
Total	$ 655	$ 566

Note 8 - Goodwill and Intangi_3

Note 8 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill	$ 431	$ 431
Acquired Finite-Lived Intangible Asset, Amortization	$ 312	$ 325
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	8 years
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	12 years
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	8 years

Note 8 - Goodwill and Intangi_4

Note 8 - Goodwill and Intangible Assets - Goodwill and Intangible Assets Balances (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Intangibles, Gross Carrying Amount	$ 5,220,000	$ 5,240,000
Intangibles, Accumulated Amortization	(640,000)	(348,000)
Intangibles, Net Carrying Amount	2,270,000
Intangibles, Net Carrying Amount	4,580,000	4,892,000
Trade Names [Member]
Intangibles, Gross Carrying Amount	2,310,000	2,310,000
Intangibles, Net Carrying Amount	2,310,000	2,310,000
Developed Technology Rights [Member]
Intangibles, Gross Carrying Amount	2,310,000	2,310,000
Intangibles, Accumulated Amortization	(598,000)	(310,000)
Intangibles, Net Carrying Amount	1,712,000	2,000,000
Intellectual Property [Member]
Intangibles, Gross Carrying Amount	460,000	460,000
Intangibles, Accumulated Amortization	(6,000)	0
Intangibles, Net Carrying Amount	454,000	460,000
Customer Relationships [Member]
Intangibles, Gross Carrying Amount	140,000	140,000
Intangibles, Accumulated Amortization	(36,000)	(18,000)
Intangibles, Net Carrying Amount	104,000	122,000
Below Market Lease [Member]
Intangibles, Gross Carrying Amount	0	20
Intangibles, Accumulated Amortization	0	(20)
Intangibles, Net Carrying Amount	$ 0	$ 0

Note 8 - Goodwill and Intangi_5

Note 8 - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details) $ in Thousands	Dec. 31, 2024 USD ($)
2025	$ 345
2026	345
2027	345
2028	345
Thereafter	890
Total	$ 2,270

Note 9 - Notes Payable, Net (De

Note 9 - Notes Payable, Net (Details Textual) - USD ($) $ in Thousands			1 Months Ended	12 Months Ended
	Dec. 05, 2022	Aug. 01, 2020	Aug. 30, 2020	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]		Prime Rate [Member]
Term Loan [Member] | PWB Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 2,000
Debt Instrument, Basis Spread on Variable Rate			0.50%
Debt Instrument, Interest Rate, Stated Percentage			4.50%
Long-Term Debt, Gross				$ 2,000
Debt Instrument, Covenant Compliance, Maximum Deposits Outside Of United States				$ 1,000
Line of Credit Facility, Interest Rate During Period				8.55%	8.81%
Interest Expense, Debt				$ 171	$ 176
Subordinated Debt [Member] | Promissory Note [Member]
Debt Instrument, Basis Spread on Variable Rate	5%
Debt Instrument, Interest Rate, Stated Percentage	0%
Long-Term Debt, Gross				3,437
Interest Expense, Debt				271	$ 320
Debt Instrument, Face Amount	$ 5,000
Debt Instrument, Periodic Payment, Number of Installments	16
Subordinated Debt				$ 4,055
Debt Instrument, Discount Rate, Percentage				7.50%
Debt Instrument, Interest Rate, Effective Percentage				7.79%	7.18%

Note 9 - Notes Payable, Net - S

Note 9 - Notes Payable, Net - Schedule of Principle Payments (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Term Loan [Member] | PWB Agreement [Member]
2026	$ 2,000
Total principal payments	2,000
Less debt discount and issuance costs	(3)
Note payable, net	1,997
Current portion	0
Long-term portion	1,997
Subordinated Debt [Member] | Promissory Note [Member]
2026	1,250
Total principal payments	3,437
Note payable, net	3,107
Current portion	1,250
Long-term portion	1,857
2025	1,250
2027	937
Less debt discount	$ (330)

Note 10 - Lease Obligations (De

Note 10 - Lease Obligations (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 31, 2022	Feb. 28, 2022
Operating Lease, Expense	$ 588	$ 548
San Rafael California [Member]
Lessee, Operating Lease, Renewal Term (Year)	3 years		3 years
Hamburg Germany [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years
Lessee, Operating Lease, Number Of Extension				1
Brecksville Ohio [Member]
Lessee, Operating Lease, Renewal Term (Year)	3 years

Note 10 - Lease Obligations - S

Note 10 - Lease Obligations - Schedule of Future Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
2025	$ 481
2026	431
2027	41
Lessee, Operating Lease, Liability, to be Paid	953
Less: imputed interest	(74)
Present value of lease liabilities	879
Lease liabilities, current	427	$ 363
Lease liabilities	452	$ 723
Total lease liabilities	$ 879
Weighted-average remaining term (in years) (Year)	1 year 10 months 24 days
Weighted-average discount rate	8.40%

Note 11 - Employee Benefit Pl_2

Note 11 - Employee Benefit Plan (Details Textual) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50%	50%
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)	163	161
Stock Issued During Period, Value, Employee Benefit Plan	$ 237	$ 249
Defined Contribution Plan, Cost	$ 257	$ 378

Note 12 - Capitalization and _3

Note 12 - Capitalization and Equity Structure (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands						1 Months Ended				12 Months Ended
	Sep. 03, 2024	Jan. 10, 2024	Feb. 28, 2021	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2024	Feb. 28, 2021	Oct. 31, 2020	Jun. 30, 2020	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2019	May 31, 2019
Common Stock, Shares Authorized (in shares)										141,429	141,429
Preferred Stock, Shares Authorized (in shares)										10,000	10,000
Common Stock, Shares, Outstanding (in shares)										22,203	14,848
Common Stock, Shares, Issued (in shares)										22,203	14,848
Preferred Stock, Shares Outstanding (in shares)										0	0
Preferred Stock, Shares Issued (in shares)										0	0
Proceeds from Issuance of Common Stock										$ 9,019	$ 661
Stock Issued During Period, Value, New Issues										$ 9,020	$ 661
Class Of Warrant Or Right Exercised (in shares)										335	0
Class Of Warrant Or Right, Issued (in shares)										14,900
Class of Warrant or Right, Outstanding (in shares)										15,560	1,240
Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 1.34
September 2024 Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,900					2,900
Shares Issued, Price Per Share (in dollars per share)						$ 1
Class Of Warrant Or Right Exercised (in shares)										335
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 0.001				$ 0.001
Proceeds from Issuance of Warrants						$ 2,897
Class Of Warrant Or Right, Issued (in shares)										2,900
Class of Warrant or Right, Outstanding (in shares)										2,565	0
September 2024 Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,000					6,000
Class Of Warrant Or Right Exercised (in shares)										0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 1				$ 1
Class Of Warrant Or Right, Issued (in shares)										6,000
Class of Warrant or Right, Outstanding (in shares)										6,000	0
Warrants and Rights Outstanding, Term (Year)										4 years 8 months 12 days
September 2024 Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,000					6,000
Class Of Warrant Or Right Exercised (in shares)										0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 1				$ 1
Class Of Warrant Or Right, Issued (in shares)										6,000
Class of Warrant or Right, Outstanding (in shares)										6,000	0
Warrants and Rights Outstanding, Term (Year)										8 months 12 days
September 2024 Warrants [Member]
Beneficial Ownership Limitation, Percentage						4.99%
Beneficial Ownership Limitation, Contingency, Percentage Increase Available for Grant						9.99%
A2021 Warrants [Member]
Class Of Warrant Or Right Exercised (in shares)										0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 12.81				$ 12.81			$ 12.81
Beneficial Ownership Limitation, Contingency, Percentage Increase Available for Grant			9.99%
Class Of Warrant Or Right, Issued (in shares)							273			0
Class of Warrant or Right, Outstanding (in shares)										273	273
Warrants and Rights Outstanding, Term (Year)										1 year 1 month 6 days
June 2020 Investor Warrants [Member]
Class Of Warrant Or Right Exercised (in shares)										0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 5.18					$ 5.18	$ 5.18
Beneficial Ownership Limitation, Contingency, Percentage Increase Available for Grant				9.99%
Class Of Warrant Or Right, Issued (in shares)										0
Class of Warrant or Right, Outstanding (in shares)				874					874	127	127
Warrants and Rights Outstanding, Term (Year)										10 months 24 days
June 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right Exercised (in shares)										0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 5.64					$ 5.64	$ 5.64
Class Of Warrant Or Right, Issued (in shares)									122	0
Class of Warrant or Right, Outstanding (in shares)										39	39
Warrants and Rights Outstanding, Term (Year)										4 months 24 days
December 2019 Warrants [Member]
Class Of Warrant Or Right Exercised (in shares)										0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 8.1					$ 8.1
Beneficial Ownership Limitation, Contingency, Percentage Increase Available for Grant					9.99%
Class Of Warrant Or Right, Issued (in shares)										0
Class of Warrant or Right, Outstanding (in shares)					556					556	556
Warrants and Rights Outstanding, Term (Year)										6 months
December 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right Exercised (in shares)										0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 8.44		$ 8.44
Class Of Warrant Or Right, Issued (in shares)										0
Class of Warrant or Right, Outstanding (in shares)										0	52	52
Warrants and Rights Outstanding, Term (Year)										0 years
May 2019 Warrants [Member]
Class Of Warrant Or Right Exercised (in shares)										0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 1.55
Class Of Warrant Or Right, Issued (in shares)										0
Class of Warrant or Right, Outstanding (in shares)										0	193		444
Warrants and Rights Outstanding, Term (Year)										0 years			5 years
September 2024 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,100
Proceeds from Issuance or Sale of Equity	$ 5,003
January 2024 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		2,968
Shares Issued, Price Per Share (in dollars per share)		$ 1.55
Proceeds from Issuance of Common Stock		$ 3,932
At the Market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)										105
Shares Issued, Price Per Share (in dollars per share)											$ 1.59
Proceeds from Issuance of Common Stock										$ 85	$ 661
Stock Issued During Period, Value, New Issues								$ 5,000
Shares Issued, Average Price Per Share (in dollars per share)										$ 1.43
Sale of Stock, Number of Shares Issued in Transaction (in shares)											451
Sale Of Stock, Stock Available For Issuance, Value										$ 4,134
At the Market Offering [Member] | Minimum [Member]
Share Price (in dollars per share)								$ 6.75

Note 12 - Capitalization and _4

Note 12 - Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details) - $ / shares shares in Thousands	1 Months Ended		12 Months Ended
	Feb. 28, 2021	Jun. 30, 2020	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024	Dec. 31, 2019	Jun. 30, 2019	May 31, 2019
Balance (in shares)			1,240
Warrants issued (in shares)			14,900
Warrants expired (in shares)			(245)
Warrants exercised (in shares)			(335)	0
Balance (in shares)			15,560	1,240
September 2024 Pre-funded Warrants [Member]
Exercise price (in dollars per share)			$ 0.001		$ 0.001
Balance (in shares)			0
Warrants issued (in shares)			2,900
Warrants expired (in shares)			0
Warrants exercised (in shares)			(335)
Balance (in shares)			2,565	0
September 2024 Series A Warrants [Member]
Exercise price (in dollars per share)			$ 1		1
Balance (in shares)			0
Warrants issued (in shares)			6,000
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)			6,000	0
Term (Year)			4 years 8 months 12 days
September 2024 Series B Warrants [Member]
Exercise price (in dollars per share)			$ 1		$ 1
Balance (in shares)			0
Warrants issued (in shares)			6,000
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)			6,000	0
Term (Year)			8 months 12 days
A2021 Warrants [Member]
Exercise price (in dollars per share)	$ 12.81		$ 12.81
Balance (in shares)			273
Warrants issued (in shares)	273		0
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)			273	273
Term (Year)			1 year 1 month 6 days
June 2020 Investor Warrants [Member]
Exercise price (in dollars per share)		$ 5.18	$ 5.18
Balance (in shares)			127
Warrants issued (in shares)			0
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)		874	127	127
Term (Year)			10 months 24 days
June 2020 Placement Agent Warrants [Member]
Exercise price (in dollars per share)		$ 5.64	$ 5.64
Balance (in shares)			39
Warrants issued (in shares)		122	0
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)			39	39
Term (Year)			4 months 24 days
December 2019 Warrants [Member]
Exercise price (in dollars per share)			$ 8.1				$ 8.1
Balance (in shares)			556
Warrants issued (in shares)			0
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)			556	556
Term (Year)			6 months
December 2019 Placement Agent Warrants [Member]
Exercise price (in dollars per share)			$ 8.44			$ 8.44
Balance (in shares)			52
Warrants issued (in shares)			0
Warrants expired (in shares)			(52)
Warrants exercised (in shares)			0
Balance (in shares)			0	52
Term (Year)			0 years
May 2019 Warrants [Member]
Exercise price (in dollars per share)			$ 1.55
Balance (in shares)			193
Warrants issued (in shares)			0
Warrants expired (in shares)			(193)
Warrants exercised (in shares)			0
Balance (in shares)			0	193
Term (Year)			0 years					5 years

Note 12 - Capitalization and _5

Note 12 - Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details)	Dec. 31, 2024	Dec. 31, 2023
A2021 Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input	0.61	2.5
A2021 Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input	12.81	12.81
A2021 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input	0.0394	0.042
A2021 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input	1.11	2.11
A2021 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input	1.067	0.765
June 2020 Investor Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input	0.61	2.5
June 2020 Investor Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input	5.18	5.18
June 2020 Investor Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input	0.0403	0.0426
June 2020 Investor Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input	0.94	1.94
June 2020 Investor Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input	0.897	0.782
June 2020 Placement Agent Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input	0.61	2.5
June 2020 Placement Agent Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input	5.64	5.64
June 2020 Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input	0.0447	0.0454
June 2020 Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input	0.44	1.44
June 2020 Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input	0.897	0.83
December 2019 Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input	0.61	2.5
December 2019 Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input	8.1	8.1
December 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input	0.0443	0.0453
December 2019 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input	0.46	1.47
December 2019 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input	0.893	0.823
December 2019 Placement Agent Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input		2.5
December 2019 Placement Agent Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input		8.44
December 2019 Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input		0.0482
December 2019 Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input	0	0.97
December 2019 Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input		0.852
May 2019 Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input		1.88
May 2019 Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input		3.52
May 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input		0.0528
May 2019 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input	0	0.4
May 2019 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input		0.775

Note 13 - Stock-based Compens_3

Note 13 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended				12 Months Ended
	Jun. 06, 2024	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2019	Dec. 31, 2015	Dec. 31, 2014
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount						$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)						0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 0	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value						$ 0	$ 58
Defined Contribution Plan, Employer Matching Contribution, Percent of Match						50%	50%
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested						$ 1,204
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount						$ 713
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						1 year 3 months 14 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						703,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 1.08
Equity Incentive Plan 2014 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	1,000,000	800,000	333,000	293,000	67,000	1,000,000	1,200,000	550,000	233,000	111,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)						4 years
Common Stock, Capital Shares Reserved for Future Issuance (in shares)											137,000
Equity Incentive Plan 2014 [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent						100%
Equity Incentive Plan 2014 [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)						10 years
Employee Stock Purchase Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)						33
Defined Contribution Plan, Employer Matching Contribution, Percent of Match						25%
Employee Stock Purchase Plan [Member] | End of Offering Period [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match						85%

Note 13 - Stock-based Compens_4

Note 13 - Stock-based Compensation - Schedule of Equity Incentive Plan Activity (Details) - Equity Incentive Plan 2014 [Member] - shares shares in Thousands		1 Months Ended				12 Months Ended
	Jun. 06, 2024	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2019	Dec. 31, 2015	Dec. 31, 2014
Shares authorized (in shares)											137
Increased in shares authorized (in shares)	1,000	800	333	293	67	1,000	1,200	550	233	111
Shares authorized (in shares)						4,724
Beginning balance (in shares)						277
Granted (in shares)						(703)
Forfeited (in shares)						49
Expired (in shares)						69
Ending balance (in shares)						692	277

Note 13 - Stock-based Compens_5

Note 13 - Stock-based Compensation - RSU and PSU Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Granted (in shares)	0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 0	$ 0
Restricted Stock Units (RSUs) [Member]
Balance (in shares)	1,305
Balance (in dollars per share)	$ 1.67
Granted (in shares)	703
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 1.08
Vested (in shares)	(934)
Vested (in dollars per share)	$ 1.75
Forfeited (in shares)	(49)
Forfeited (in dollars per share)	$ 1.76
Balance (in shares)	1,025	1,305
Balance (in dollars per share)	$ 1.22	$ 1.67

Note 13 - Stock-based Compens_6

Note 13 - Stock-based Compensation - Stock Option Outstanding (Details) - Equity Incentive Plan 2014 [Member] $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Outstanding at beginning of year (in shares) | shares	251
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 36.19
Forfeited (in shares) | shares	0
Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Expired (in shares) | shares	(68)
Expired, weighted average exercise price (in dollars per share) | $ / shares	$ 48.61
Outstanding at end of year (in shares) | shares	183
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 31.53
Outstanding at end of year (Year)	3 years 7 months 2 days
Outstanding at end of year | $	$ 0
Vested and expected to vest (in shares) | shares	183
Vested and expected to vest, weighted average exercise price (in dollars per share) | $ / shares	$ 31.53
Vested and expected to vest (Year)	3 years 6 months 29 days
Vested and expected to vest | $	$ 0
Exercisable at year end (in shares) | shares	183
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 31.53
Exercisable at year end (Year)	3 years 7 months 2 days
Exercisable at year end | $	$ 0

Note 13 - Stock-based Compens_7

Note 13 - Stock-based Compensation - Schedule of Options by Exercise Price (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Options outstanding, number of shares (in shares) | shares	183,000
Options outstanding, weighted-average remaining contractual life (Year)	3 years 7 months 17 days
Options outstanding, weighted average price (in dollars per share)	$ 31.53
Options exercisable, number of shares (in shares) | shares	183,000
Options exercisable, weighted average price (in dollars per share)	$ 31.53
Exercise Price Range 1 [Member]
Exercise price, minimum (in dollars per share)	5.55
Exercise price, maximum (in dollars per share)	$ 5.7
Options outstanding, number of shares (in shares) | shares	47,000
Options outstanding, weighted-average remaining contractual life (Year)	5 years 18 days
Options outstanding, weighted average price (in dollars per share)	$ 5.69
Options exercisable, number of shares (in shares) | shares	47,000
Options exercisable, weighted average price (in dollars per share)	$ 5.69
Exercise Price Range 2 [Member]
Exercise price, minimum (in dollars per share)	9.15
Exercise price, maximum (in dollars per share)	$ 26.39
Options outstanding, number of shares (in shares) | shares	62,000
Options outstanding, weighted-average remaining contractual life (Year)	3 years 11 months 12 days
Options outstanding, weighted average price (in dollars per share)	$ 16.88
Options exercisable, number of shares (in shares) | shares	62,000
Options exercisable, weighted average price (in dollars per share)	$ 16.86
Exercise Price Range 3 [Member]
Exercise price, minimum (in dollars per share)	26.85
Exercise price, maximum (in dollars per share)	$ 54.15
Options outstanding, number of shares (in shares) | shares	47,000
Options outstanding, weighted-average remaining contractual life (Year)	3 years 3 months 25 days
Options outstanding, weighted average price (in dollars per share)	$ 31.69
Options exercisable, number of shares (in shares) | shares	47,000
Options exercisable, weighted average price (in dollars per share)	$ 31.71
Exercise Price Range 4 [Member]
Exercise price, minimum (in dollars per share)	60
Exercise price, maximum (in dollars per share)	$ 196.35
Options outstanding, number of shares (in shares) | shares	27
Options outstanding, weighted-average remaining contractual life (Year)	1 year 10 days
Options outstanding, weighted average price (in dollars per share)	$ 108.43
Options exercisable, number of shares (in shares) | shares	27
Options exercisable, weighted average price (in dollars per share)	$ 108.43

Note 13 - Stock-based Compens_8

Note 13 - Stock-based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Stock based compensation	$ 1,373	$ 1,858
Selling and Marketing Expense [Member]
Stock based compensation	98	260
Research and Development Expense [Member]
Stock based compensation	220	423
General and Administrative Expense [Member]
Stock based compensation	$ 1,055	$ 1,175

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Current Federal, State and Local, Tax Expense (Benefit)	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 1,556	$ 4,269
Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs	3,900	$ 4,700
Domestic Tax Jurisdiction [Member]
Operating Loss Carryforwards	$ 203,860
Open Tax Year	2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Domestic Tax Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 2,353
Domestic Tax Jurisdiction [Member] | Generated Before 2018 [Member]
Operating Loss Carryforwards	120,792
Domestic Tax Jurisdiction [Member] | Generated After 2017 [Member]
Operating Loss Carryforwards	83,068
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	133,371
Open Tax Year		2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	752
Foreign Tax Jurisdiction [Member]
Operating Loss Carryforwards	$ 12,552
Foreign Tax Jurisdiction [Member] | Federal Ministry of Finance, Germany [Member]
Open Tax Year	2019 2020 2021 2022 2023 2024
Foreign Tax Jurisdiction [Member] | Inland Revenue, Singapore (IRAS) [Member]
Open Tax Year	2020

Note 14 - Income Taxes - Schedu

Note 14 - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Domestic	$ (11,576)	$ (13,521)
Foreign	246	(1,677)
Loss before income taxes	$ (11,330)	$ (15,198)

Note 14 - Income Taxes - Sche_2

Note 14 - Income Taxes - Schedule of Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Federal tax at statutory rate	21%	21%
State tax, net of federal tax effect	0%	0%
Research and development credit	(0.10%)	1.10%
Change in valuation allowance	(13.50%)	(12.50%)
Unrealized gain on warrant	0.70%	(0.20%)
Stock-based compensation	(4.70%)	(1.70%)
Other	(2.80%)	(0.70%)
Foreign	(0.60%)	(7.00%)
Total tax expense (benefit)	0%	0%

Note 14 - Income Taxes - Sche_3

Note 14 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Depreciation and other	$ 119	$ 136
Net operating loss carryforwards	54,001	52,448
Research and development tax credits	2,210	2,219
Accruals and reserves	235	311
Capitalized research and development costs	1,817	1,422
Deferred revenue	400	220
Stock compensation expense	1,028	1,493
Lease assets	154	178
Other	48	50
Lease liabilities	(133)	(152)
Prepaid expenses	(54)	(56)
Less: Valuation allowance	(59,825)	(58,269)
Net deferred tax asset (liability)	$ 0	$ 0

Note 14 - Income Taxes - Sche_4

Note 14 - Income Taxes - Schedule of Unrecognizable Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Beginning balances as of January 1, 2024 and 2023	$ 1,894	$ 716
Decrease of unrecognized tax benefits taken in prior years	(58)
Increase of unrecognized tax benefits taken in prior years		9
Increase of unrecognized tax benefits related to current year	0	1,169
Ending balances as of December 31, 2024 and 2023	$ 1,836	$ 1,894

Note 15 - Commitments and Con_3

Note 15 - Commitments and Contingencies (Details Textual) $ in Thousands			12 Months Ended
	Mar. 01, 2022 USD ($)	Oct. 15, 2012 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Number Of License Agreements			2
Purchase Obligation			$ 1,263	$ 2,783
Long-Term Purchase Commitment, Period (Year)			1 year
Lessee, Operating Lease, Liability, to be Paid			$ 953
Royalty Agreement Terms [Member]
Royalty Percentage		3.75%
Royalty Expense	$ 75	$ 250	$ 100
Royalty Agreement Terms [Member] | Licensed Patent Products [Member]
Royalty Percentage		6%
Royalty Agreement Terms [Member] | Licensed Software Products [Member]
Royalty Percentage		3%
Sales Revenue Goods Net Excluding Government Sales [Member] | Royalty Agreement Terms [Member]
Royalty Percentage			1%
License Revenue [Member] | Royalty Agreement Terms [Member]
Royalty Percentage			21%

Note 15 - Commitments and Con_4

Note 15 - Commitments and Contingencies - Schedule of Other Commitments (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Contractual obligation	$ 6,650
Contractual obligation, less than one year	1,887
Contractual obligation, one to three years	4,763
Facility Operating Lease [Member]
Contractual obligation	953
Contractual obligation, less than one year	481
Contractual obligation, one to three years	472
Term Loan [Member]
Contractual obligation	2,260
Contractual obligation, less than one year	156
Contractual obligation, one to three years	2,104
Notes Payable, Other Payables [Member]
Contractual obligation	3,437
Contractual obligation, less than one year	1,250
Contractual obligation, one to three years	$ 2,187

Note 17 - Related Party Trans_2

Note 17 - Related Party Transactions (Details Textual) - Angel Pond Capital LLC [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Related Party Transaction, Amounts of Transaction	$ 325
Related Party Transaction, Payment Term (Year)	14 years
Accounts Payable	$ 0	$ 60
Initial Payment1 [Member]
Related Party Transaction, Amounts of Transaction	$ 145
Related Party Transaction, Payment Term (Year)	40 months
Initial Payment [Member]
Related Party Transaction, Amounts of Transaction	$ 15
Initial Payment2 [Member]
Related Party Transaction, Payment Term (Year)	12 years